Introduction
Candidemia is a serious health careerelated infection and is associated with a poor prognosis. The incidence of candidemia is increasing significantly in recent years. It is the fourth common cause of bloodstream infections (BSIs) in U.S. hospitals and the leading cause of nosocomial BSIs in some hospitals in Taiwan. 1e4 The major risk factors for candidemia include intravascular catheters, parenteral hyperalimentation, and broad-spectrum antibiotics. In terms of Candida spp., a recent shift from Candida albicans to non-albicans has been reported. 5, 6 Non-albicans candidemia (NAC) has been shown to be responsible for 36e63% of all candidemia cases. 7e9 Furthermore, certain Candida spp., such as Candida glabrata, have a tendency toward decreased susceptibility to fluconazole, and others, such as Candida krusei, are resistant to fluconazole. 10, 11 Several reports have suggested that delayed initiation of antifungal therapy for candidemia is associated with increased mortality. 12, 13 NAC patients tend to be less susceptible to fluconazole than C albicans candidemia patients. 14e16 Thus, early and appropriate usage of antifungal therapy is important for NAC. In the present study, we compared the risk factors and prognosis of patients with C albicans candidemia and NAC.
Methods

Patient enrollment and data collection
We retrospectively evaluated the medical and microbiological data of all cases of candidemia in Tri-Service General Hospital from October 2007 to July 2009. Demographic data, comorbidities, microbiological data, and patients' outcomes were evaluated. The inclusion criteria comprised age greater than 16 years and at least one positive blood culture yielding Candida. Patients with candidemia caused by more than one species were excluded. For patients with multiple candidemic episodes, only the first episode was included.
Mycological studies
Blood cultures of present cases were performed using BacT/ALERT Microbial Detection System (bioMèrieux SA, Marcy-l'Etoile, France). The isolates of the present cases initially grew on Sabouraud dextrose agar and then identified in our laboratory by morphological (CHROMagar and corn meal agar; Beckton, Dickinson and Company, Paris, France) and biochemical methods (Vitek 2 YST, bioMèrieux, USA). Susceptibility to antifungal agents was tested by the ATB Fungus 3 system (bioMèrieux SA) according to the manufacturer's instructions. Two reference strains, Candida parasilosis ATCC 22019 and C krusei ATCC 6258, were used as control strains for susceptibility testing. The reference breakpoints of minimal inhibition concentrations (MICs) were defined by Clinical and Laboratory Standards Institute in 2008. MICs less than or equal to 4, less than or equal to 8, less than or equal to 0.125, and less than or equal to 1 were considered susceptible to flucytosine, fluconazole, itraconazole, and voriconazole, respectively. Interpretive breakpoints for amphotericin B have not been established by the Clinical and Laboratory Standards Institute. Clinical and Laboratory Standards Institute developed and published an approved reference method for broth microdilution testing of yeast. 17e19 The acceptable percent essential agreement for MICs was set at greater than or equal to 90% for each antifungal agent against all organisms tested.
Study variables
Clinical data, including age at the time of diagnosis, gender, and underlying diseases, of 108 patients with candidemia were recorded on standardized forms. Diseases, including alcoholism, liver cirrhosis, heart failure, renal failure, solid organ malignancy, hematologic malignancy, diabetes, and neutropenia, were recorded. Predisposing factors that occurred within 30 days before the onset of candidemia were also collected. These included central venous catheter usage; presence of a prosthesis, implant, or indwelling of urinary catheter; receipt of mechanical ventilation; total parental nutrition or peripheral parental nutrition usage; receipt of corticosteroids; blood product transfusions; hemodialysis; gastrointestinal procedures and operations; concomitant infections; bacteremia; total number of antibiotics; candiduria; exposure to antifungal agents; and intensive care unit (ICU) stay. Laboratory data within 7 days before obtaining the first positive blood culture were analyzed.
Definitions
Candidemia was defined as at least one positive blood culture for Candida spp. in patients with symptoms or signs of infection. Neutropenia was defined as an absolute neutrophil count less than 500 cells/mL or less than 1,000 cells/mL, with a predicted nadir of less than 500 cells/mL. Presence of prosthesis/implant was defined as Port-A or peripherally inserted central catheter implantation. Receipt of corticosteroids was defined as the usage of a dose equivalent to at least 20 mg prednisolone per day for more than 7 days within 4 weeks of the onset of candidemia. Candiduria was defined as the presence of more than 100,000 CFU/mL of Candida spp. in the urine sample obtained within 1 month of the candidemia. Gastrointestinal procedures and operations included endoscopic retrograde cholangiopancreatography; use of biliary tubes and percutaneous endoscopic gastrostomy tubes; and other abdominal surgical procedures. All-cause Day 7 mortality was defined as death that occurred within 1 week of the onset of candidemia. All-cause in-hospital mortality was defined as all death that occurred during hospitalization after the onset of candidemia. The severity of the initial presentation of candidemia was assessed by the Acute Physiology and Chronic Health Evaluation (APACHE) III score after the occurrence of candidemia.
Statistical analysis
All statistical analyses were performed by using the SPSS for windows (Version 15.0; SPSS, Chicago, IL, USA). Univariate analysis using Pearson c 2 test (for categorical measures) and unpaired Student's t test (for continuous measures) were performed to demonstrate the correlation of the possible risk factors of all-cause Day 7 mortality. A p value less than 0.05 was considered statistically significant. Multivariate analyses were performed to identify the independent factors associated with all-cause Day 7 mortality by using stepwise logistic regression.
Results
One hundred and eight patients of candidemia were enrolled in our study. Candida albicans and non-albicans spp. were responsible for 56.5% (61 of 108) and 43.5% (47 of 108) of candidemia cases, respectively. The distribution of C non-albicans spp. was as follows: C glabrata, 17.6% (19 of 108); Candida tropicalis, 13.0% (14 of 108); C parasilosis, 11.1% (12 of 108); C krusei, 1% (1 of 108); and Candida haemonulonii, 1% (1 of 108) ( Table 1) .
Among patients with NAC, significantly more patients had neutropenia (p Z 0.001), and less patients had candiduria (p Z 0.001) and ICU stay (p Z 0.002) ( Table 2 ). The patients with receipt of mechanical ventilation (p Z 0.109) and indwelling of urinary catheter (p Z 0.097) tend to have more C albicans BSIs when compared with non-albicans BSIs. However, these trends did not reach statistical significance.
Susceptibility to itraconazole between patients with C albicans BSIs and C non-albicans BSIs was statistically different [95.1% (58 of 61) vs. 61.7% (29 of 47), p < 0.001] ( Table 3 ). The in vitro susceptibilities of Candida spp. to antifungal agents are listed in Table 4 .
Among patients with candidemia, all-cause Day 7 mortality rate was 38.0% (41 of 108). Day 7 mortality rates of C albicans and NAC were demonstrated as 44.3% (27 of 61) and 29.8% (14 of 47) ( Table 3 ). The respective all-cause Day 7 mortality rates among NAC were as follows: C glabrata, 31.6% (6 of 19); C tropicalis, 42.9% (6 of 14); C parasilosis, 8.3% (1 of 12); C krusei, 100% (1 of 1); and Candida haemulonii, 0% (0 of 1) ( Table 1 ). Excluding patients with candidemia of C krusei and C haemulonii because of the small number of cases, patients with C albicans candidemia had the highest rate (44.2%) of all-cause Day 7 mortality, whereas those with C parasilosis candidemia had the lowest mortality rate. The crude all-cause in-hospital mortality rate was 55.6% (60 of 108). Patients with candidemia with poor outcome have been demonstrated. Using univariate analysis, receipt of corticosteroids (p Z 0.018); blood product transfusion (p Z 0.003); hemodialysis (p Z 0.012); thrombocytopenia (p Z 0.001); poor renal function (judged by blood urea nitrogen and creatinine, p < 0.001 respectively); and shock (p < 0.001) were found to be significantly associated with all-cause Day 7 mortality (Table 5) . By multivariate analysis, only poor renal function (odds ratio, 1.035; 95% confidence interval, 1.001e1.071; p Z 0.04) and shock (odds ratio, 19.4; 95% CI, 2.53e149.5; p Z 0.004) were found to be independently associated with all-cause Day 7 mortality (Table 6 ).
Discussion
During the 22-month period of this survey, C albicans accounted for 56.5% of all candidemia cases in this study, which is higher than the reports of another tertiary care hospital in northern Taiwan (48%), lower than those of central Taiwan (64.8%), but close to those of the United States (55%) and Europe (58%). 20e22 Even though C albicans remains the most common species causing candidemia, the proportion of NAC is increasing. 8, 14 The proportion of NAC in our study is 17.6% for C glabrata, 13.0% for C tropicalis, 11.1% for C parasilosis. Our results are in accordance with the conclusions of previously published studies in two populations: diabetic and ICU patients. 9, 23 Patients with NAC are more likely to require greater dosage of fluconazole to cure clinically. 24, 25 Thus, there is a need to identify patients at risk of NAC to initiate empirical amphotericin B therapy or high-dose fluconazole.
In our study, we found that an increased risk of NAC was associated with neutropenia (p Z 0.001). Other published studies found that NAC has been associated with factors, such as neutropenia, hematologic malignancies, allogenic stem cell transplantation, illness severity, and prior fluconazole prophylaxis. 5,26e28 Among patients with albicans candidemia, significantly more patients had candiduria (p Z 0.001) and ICU stay (p Z 0.002). This phenomenon can be explained by the spectrum in the extent of adherence to tissues, which correlates with the pathogenicity in humans and animals. 29 Candida albicans exhibits the greatest capacity to adhere to gingival epithelial cells, followed by C tropicalis and C glabrata.
Furthermore, there is no significant difference in the antifungal susceptibilities between NAC and C albicans, except to itraconazole. This may be the result of the relatively small number of cases of C krusei in our study and the antifungal susceptibilities among our patients with C glabrata candidemia. Our patients with C glabrata candidemia have 100% susceptibility rate to fluconazole. However, fluconazole susceptibility and the choice of antifungal regimen were not correlated with mortality. Some studies also reported that patients with candidemia were often seriously ill, and the outcome appeared to be associated with the underlying conditions rather than with fluconazole susceptibility or antifungal agents. 30e32 All-cause Day 7 mortality was high in both patients with C albicans and C non-albicans spp. BSIs in our study (44.3% and 29.8%, respectively). Our findings suggest that patients with C parasilosis candidemia have the lowest mortality rate (8.3%); this finding is consistent with the result of prior studies. 5, 33, 34 Candida infections are not solely related to the pathogenicity of the Candida spp., but also to a failure of host-defense mechanisms and to complications associated with the patients underlying disease. 35 The more severely ill patients are at a higher risk of Candida infection and have a worse prognosis. This is particularly evident in ICU patients who require indwelling central venous catheter and receipt of mechanical ventilation. Furthermore, C albicans is known to be more virulent than NAC. 26, 36 These factors may explain the higher all-cause Day 7 mortality rate among patients with C albicans BSIs.
APACHE II score was the most common independent predictor of candidemia-related mortality in other institutions of Taiwan. 22, 37 In our study, higher APACHE III score at the onset of candidemia trended toward an increased risk of all-cause Day 7 mortality (p Z 0.111), compared with nonmortality, but the difference did not reach statistical significance. The overall all-cause in-hospital mortality rate in this study was found to be 55.6%, which is compatible with previous reports of candidemia, in which a rate of 40e76% was noted. 13, 30, 38 Univariate analysis revealed the receipt of corticosteroids, blood product transfusion, and hemodialysis to be the risk factors for all-cause Day 7 mortality among candidemic patients. Administration of glucocorticosteroids reduces chemotaxis, phagocytosis, and phagosomal function. This may contribute to all-cause Day 7 mortality of candidemic patients. However, poor renal function and shock were the only two independent factors for all-cause Day 7 mortality in the multivariate analysis. In clinical practice, these factors could be considered as warning signs of candidemia.
In conclusion, this article defines a number of factors with an increased risk of candidemia because of NAC compared with C albicans candidemia. Our findings suggest that neutropenia was associated with an increased risk and that candiduria and ICU stay were associated with decreased risk of BSI because of NAC. Candidemia is associated with a poor outcome and a high mortality rate. The independent risk factors identified in this study, such as poor renal function and shock, may help us, in clinical practice, to differentiate fatal candidemia from nonfatal candidemia. 
